GlassScriptPhysician profile
Rodney A Brown
NPI 1639174337
$2,789.37
in general payments reported to CMS, 2019-2025
18 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $190 · 2021: $384 · 2022: $1,031 · 2023: $225 · 2024: $388 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $776.52 | 2021-2025 | Onyx Frontier, Symplicity G3, Corevalve Evolut R |
| Abbott Laboratories | $373.14 | 2022 | |
| Philips North America LLC | $299.31 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $293.62 | 2021-2023 | |
| Boston Scientific Corporation | $179.83 | 2020-2023 | Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $176.92 | 2019-2023 | Repatha |
| Impulse Dynamics (USA) INC. | $130.82 | 2022 | |
| Biotronik INC. | $119.14 | 2024 | Orsiro Mission |
| Actelion Pharmaceuticals US, INC. | $108.94 | 2019-2024 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $86.49 | 2021-2024 | |
| Amarin Pharma, INC. | $52.62 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $44.86 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $35.03 | 2022 | |
| Cardiovascular Systems INC. | $33.52 | 2019-2021 | |
| Abiomed | $32.04 | 2019-2023 | Impella |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $18.39 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $15.61 | 2024 | Arcalyst |
| Terumo Medical Corporation | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.